Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 2/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.41 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 3/20 | 0.41 |
| ▸ | CCR5 | P51681 | 3/20 | 0.41 |
| ▸ | CCR8 | P51685 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8623707 | 0.85 | CCR1 (0.55) | GPR39CBFBSCDKDM4AKDM4B | |
| SCHEMBL3664279 | 0.79 | LOXL2 (0.46) | GPR39CBFBSCDKDM4AKDM4B | |
| SCHEMBL15402037 | 0.77 | KDM4A (0.46) | GPR39CBFBSCDKDM4AKDM4B | |
| SCHEMBL9677009 | 0.76 | CCR1 (0.51) | GPR39CBFBSCDKDM4AKDM4B | |
| SCHEMBL8512862 | 0.75 | GPR39 (0.46) | GPR39CBFBSCDKDM4AKDM4B | |
| SCHEMBL17850531 | 0.75 | NPY5R (0.50) | GPR39KDM4AKDM4BKDM5CKDM5B | |
| SCHEMBL8513636 | 0.74 | HSP90AA1 (0.54) | CCR1CCR5CCR8KDM4ELMNA | |
| SCHEMBL15217633 | 0.72 | KDM4E (0.63) | CCR1CCR5CCR8KDM4ELMNA | |
| Dipyridyl SCHEMBL27645628 | 0.71 | KDM4E (0.64) | KDM4AKDM5CPTGS2CCR1CCR5 | |
| SCHEMBL5022939 | 0.70 | CCR1 (0.44) | GPR39CBFBSCDKDM4AKDM4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| EP-2643299-B1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA SA (ES) | 2016-06-22 | — | — | EP | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284296-B2 | Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions | AUBERGINE PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-20140005195-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| EP-2643299-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | Noscira, S.A. (ES) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012069428-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069428-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | NOSCIRA, S.A. (ES) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005195-A1 | BIPYRIDINE SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES OR CONDITIONS | SNCA, PSEN2, PSEN1 | GPR39 1980/4885CBFB 2133/4885SCD 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.